文献速递心外重症与机械循环支持

两种离心式左心室辅助装置血液相容性的体外比较

In vitro comparison of the hemocompatibility of two centrifugal left ventricular assist devices.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-08-06

该体外研究利用8名健康志愿者全血在模拟环路中循环6小时,比较HeartMate 3与EVAHEART两种离心式左心室辅助装置的血液相容性。结果显示EVAHEART在最佳转速和等转速条件下均产生更低的游离血浆血红蛋白和凝血酶-抗凝血酶复合物,且更好地保留了血管性血友病因子功能活性,提示装置设计对减少血液损伤具有重要作用。

要点

  • EVAHEART在两种转速设置下游离血浆血红蛋白均显著低于HeartMate 3。
  • 两种装置均导致血管性血友病因子高分子量多聚体丢失,但HeartMate 3最佳转速下功能活性比值更低。
  • EVAHEART的凝血酶-抗凝血酶复合物水平在两种设置下均显著更低。

核心结论

  • EVAHEART左心室辅助装置较HeartMate 3引起更少溶血、更低凝血激活并更好保留血管性血友病因子功能活性。
  • 左心室辅助装置设计对减少支持期间血液损伤起重要作用。

研究设计与样本

  • 体外研究,使用8名健康志愿者全血在微型模拟环路中循环6小时。
  • 同一供者血液用于两种实验设置:最佳转速(HeartMate 3 5000 rpm,n=4;EVAHEART 2500 rpm,n=4)和等转速3000 rpm(n=4 vs n=4)。
  • 血流量调整为每分钟1个模拟环路填充体积(HeartMate 3 82 mL/min,EVAHEART 100 mL/min)。

主要发现

  • 6小时循环后游离血浆血红蛋白在EVAHEART组显著低于HeartMate 3组:最佳转速37 ± 31 vs 503 ± 173 mg/dL,P < .0001;等转速27 ± 4 vs 139 ± 135 mg/dL,P = .024。
  • 两种装置和两种设置下均发生血管性血友病因子高分子量多聚体丢失,但6小时后血管性血友病因子活性/抗原比值在HeartMate 3最佳转速设置下显著更低(P = .009)。
  • 凝血酶-抗凝血酶复合物水平在EVAHEART两种设置下均显著更低(P < .0001)。

临床怎么用

  • 对于需要左心室辅助装置支持的患者,选择血液相容性更优的装置可能减少溶血和凝血激活相关并发症。
  • 临床监测左心室辅助装置患者时应关注溶血标志物和血管性血友病因子功能状态。

局限性

  • 研究为体外模拟环路实验,使用健康志愿者血液,不能完全代表体内病理生理环境。
  • 样本量小(每组n=4),观察时间为6小时,长期血液相容性未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Shear stress from left ventricular assist devices induces von Willebrand factor degradation and platelet dysfunction, leading to nonsurgical bleeding. We characterized the hemostatic changes induced by 2 centrifugal left ventricular assist devices, the HeartMate 3 (Abbott Inc, Chicago, Ill) and the EVAHEART (Evaheart Inc, Houston, Tex), for comparison. METHODS: Whole blood from 8 healthy volunteers was used ex vivo. Blood from the same donor was used for 6 hours of circulation in a miniature mock-loop system consisting of 2 identical extracorporeal circuits to compare the following experimental settings: (1) optimal revolutions per minute (rpm) for the HeartMate 3 (n = 4; 5000 rpm) and the EVAHEART (n = 4; 2500 rpm) and (2) equal rpm (3000 rpm for the HeartMate 3 and EVAHEART, n = 4 vs n = 4). For both settings, blood flow was adjusted to 1 mock-loop filling volume per minute (HeartMate 3 = 82 mL/min, EVAHEART = 100 mL/min). A panel of coagulation markers was analyzed to investigate hemostatic changes. RESULTS: The free plasma hemoglobin concentration was significantly lower in the EVAHEART compared with the HeartMate 3 after 6 hours of mock-loop circulation under both settings (optimal: 37 ± 31 vs 503 ± 173 mg/dL, P < .0001; equal: 27 ± 4 vs 139 ± 135 mg/dL, P = .024). Loss of von Willebrand factor high-molecular-weight multimers occurred in both left ventricular assist devices and settings, but the von Willebrand factor:activity/von Willebrand factor:antigen ratio after 6 hours was significantly lower in optimal settings for the HeartMate 3 (P = .009). The thrombin-antithrombin complex level was significantly lower with the EVAHEART for both settings (P < .0001). CONCLUSIONS: The EVAHEART left ventricular assist device caused less hemolysis, resulted in lower coagulation activation, and provided better preservation of von Willebrand factor functional activity compared with the HeartMate 3 device. These findings prove that left ventricular assist device design plays a major role in minimizing blood damage during left ventricular assist device support.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Zayat R, Moza A, Grottke O, et al. In vitro comparison of the hemocompatibility of two centrifugal left ventricular assist devices. J Thorac Cardiovasc Surg. 2018. PMID: 30414772. doi:10.1016/j.jtcvs.2018.07.085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。